Published in Am J Med Sci on October 14, 1981
Eikenella corrodens endocarditis: case report and review of the literature. Can Med Assoc J (1983) 0.90
Eikenella corrodens endocarditis in an intravenous drug user: case report and literature review. J Natl Med Assoc (1994) 0.81
Infective endocarditis due to Eikenella corrodens: Case report and review of the literature. Can J Infect Dis (1990) 0.79
Structural analysis of haemoglobin binding by HpuA from the Neisseriaceae family. Nat Commun (2015) 0.77
Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. National Institute of Allergy and Infectious Diseases Mycoses Study Group and AIDS Clinical Trials Group. N Engl J Med (1997) 5.88
Candida glabrata: review of epidemiology, pathogenesis, and clinical disease with comparison to C. albicans. Clin Microbiol Rev (1999) 5.84
Practice guidelines for the treatment of candidiasis. Infectious Diseases Society of America. Clin Infect Dis (2000) 5.73
Practice guidelines for the management of cryptococcal disease. Infectious Diseases Society of America. Clin Infect Dis (2000) 5.53
Urinary tract infection: self-reported incidence and associated costs. Ann Epidemiol (2000) 4.26
Detection of circulating candida enolase by immunoassay in patients with cancer and invasive candidiasis. N Engl J Med (1991) 4.20
Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial. Lancet (2005) 4.17
Fungemia caused by Candida species and Torulopsis glabrata in the hospitalized patient: frequency, characteristics, and evaluation of factors influencing outcome. Rev Infect Dis (1989) 4.01
Epidemiology and pathogenesis of recurrent vulvovaginal candidiasis. Am J Obstet Gynecol (1985) 3.97
Antibiotic synergism in enterococcal endocarditis. J Lab Clin Med (1976) 3.79
First human trial of a DNA-based vaccine for treatment of human immunodeficiency virus type 1 infection: safety and host response. J Infect Dis (1998) 3.60
Emerging role of lactobacilli in the control and maintenance of the vaginal bacterial microflora. Rev Infect Dis (1990) 3.19
In vitro activity of a new pneumocandin antifungal, L-743,872, against azole-susceptible and -resistant Candida species. Antimicrob Agents Chemother (1997) 3.17
Critical role of germ tube formation in the pathogenesis of candidal vaginitis. Infect Immun (1984) 3.07
The vaginal microbiome: new information about genital tract flora using molecular based techniques. BJOG (2011) 2.41
Adherence of Candida albicans to human vaginal and buccal epithelial cells. J Infect Dis (1981) 2.27
Double-blind controlled comparison of phlebitis produced by cephapirin and cephalothin. Antimicrob Agents Chemother (1973) 2.26
Prospective multicenter surveillance study of funguria in hospitalized patients. The National Institute for Allergy and Infectious Diseases (NIAID) Mycoses Study Group. Clin Infect Dis (2000) 2.15
Nosocomial Pseudomonas cepacia infection associated with chlorhexidine contamination. Am J Med (1982) 2.14
A comparison of itraconazole versus fluconazole as maintenance therapy for AIDS-associated cryptococcal meningitis. National Institute of Allergy and Infectious Diseases Mycoses Study Group. Clin Infect Dis (1999) 2.14
Comparison of restriction enzyme analysis and pulsed-field gradient gel electrophoresis as typing systems for Candida albicans. J Clin Microbiol (1991) 2.12
Candida-specific cell-mediated immunity is demonstrable in mice with experimental vaginal candidiasis. Infect Immun (1993) 2.08
Validity of the vaginal gram stain for the diagnosis of bacterial vaginosis. Obstet Gynecol (1996) 2.07
Alopecia associated with fluconazole therapy. Ann Intern Med (1995) 2.05
Immunopathogenesis of recurrent vulvovaginal candidiasis. Clin Microbiol Rev (1996) 1.90
Risk factors for second urinary tract infection among college women. Am J Epidemiol (2000) 1.88
Kikuchi-Fujimoto disease: a benign cause of fever and lymphadenopathy. Am J Med (1996) 1.85
Candida-specific Th1-type responsiveness in mice with experimental vaginal candidiasis. Infect Immun (1993) 1.84
Nosocomial acquisition of Candida albicans: an epidemiologic study. J Infect Dis (1993) 1.81
Recurrent vulvovaginal candidiasis. A prospective study of the efficacy of maintenance ketoconazole therapy. N Engl J Med (1986) 1.81
Liver abscess caused by Streptococcus milleri. Rev Infect Dis (1989) 1.71
Torulopsis glabrata vaginitis: clinical aspects and susceptibility to antifungal agents. Obstet Gynecol (1990) 1.69
Effects of preinduced Candida-specific systemic cell-mediated immunity on experimental vaginal candidiasis. Infect Immun (1994) 1.68
Development and verification of fingerprinting probes for Candida glabrata. Microbiology (1997) 1.67
Vulvovaginal candidiasis--what we do and do not know. Ann Intern Med (1984) 1.67
Management of recurrent vulvovaginal candidiasis with intermittent ketoconazole prophylaxis. Obstet Gynecol (1985) 1.64
Antibiotic concentrations in serum, serum bactericidal activity, and results of therapy of streptococcal endocarditis in rabbits. Antimicrob Agents Chemother (1977) 1.64
Polymorphonuclear leucocyte function in Behçet's disease. J Clin Pathol (1977) 1.59
Weekly fluconazole for the prevention of mucosal candidiasis in women with HIV infection. A randomized, double-blind, placebo-controlled trial. Terry Beirn Community Programs for Clinical Research on AIDS. Ann Intern Med (1997) 1.58
Micafungin: a new echinocandin. Clin Infect Dis (2006) 1.58
Nosocomial Candida glabrata colonization: an epidemiologic study. J Clin Microbiol (1998) 1.57
Circulating CD4 and CD8 T cells have little impact on host defense against experimental vaginal candidiasis. Infect Immun (1995) 1.56
The effect of acute severe illness on CD4+ lymphocyte counts in nonimmunocompromised patients. Arch Intern Med (2000) 1.55
A randomized clinical trial of granulocyte transfusions for infection in acute leukemia. N Engl J Med (1977) 1.51
Comparison of restriction enzyme analysis versus pulsed-field gradient gel electrophoresis as a typing system for Torulopsis glabrata and Candida species other than C. albicans. J Clin Microbiol (1993) 1.49
Need for alternative trial designs and evaluation strategies for therapeutic studies of invasive mycoses. Clin Infect Dis (2001) 1.48
Eosinophilic meningitis due to Angiostrongylus cantonensis in a returned traveler: case report and review of the literature. Clin Infect Dis (2001) 1.48
Mice immunized by primary vaginal Candida albicans infection develop acquired vaginal mucosal immunity. Infect Immun (1995) 1.48
Treatment of experimental Staphylococcus aureus endocarditis: comparison of cephalothin, cefazolin, and methicillin. Antimicrob Agents Chemother (1978) 1.47
Experimental chronic vaginal candidosis in rats. Sabouraudia (1985) 1.46
Systemic cell-mediated immune reactivity in women with recurrent vulvovaginal candidiasis. J Infect Dis (1993) 1.45
Minimal concentrations of aminoglycoside that can synergize with penicillin in enterococcal endocarditis. Antimicrob Agents Chemother (1981) 1.43
Comparison of methicillin, nafcillin, and oxacillin in therapy of Staphylococcus aureus endocarditis in rabbits. J Lab Clin Med (1977) 1.42
Epidemiology of recurrent vulvovaginal candidiasis: identification and strain differentiation of Candida albicans. J Infect Dis (1986) 1.42
Cure of Aspergillus ustus endocarditis on a prosthetic valve. Arch Intern Med (1974) 1.41
Bacterial adherence in the pathogenesis of urinary tract infection: a review. Rev Infect Dis (1987) 1.41
Comparative in vitro activity of antimycotic agents against pathogenic vaginal yeast isolates. J Med Vet Mycol (1994) 1.38
Clinical, microbiological, and biochemical factors in recurrent bacterial vaginosis. J Clin Microbiol (1992) 1.38
A murine model of Candida glabrata vaginitis. J Infect Dis (1996) 1.35
Growth inhibition of Candida albicans by human vaginal epithelial cells. J Infect Dis (2001) 1.35
Nosocomial acquisition of Candida parapsilosis: an epidemiologic study. Am J Med (1993) 1.31
Bacterial vaginosis: treatment with clindamycin cream versus oral metronidazole. Obstet Gynecol (1992) 1.28
The role of cell-mediated immunity in candidiasis. Trends Microbiol (1994) 1.27
Ketoconazole in the prevention of experimental candidal vaginitis. Antimicrob Agents Chemother (1984) 1.26
Chronic vulvovaginal candidiasis: characteristics of women with Candida albicans, C glabrata and no candida. Genitourin Med (1995) 1.23
Histohogical and direct immunofluorescence study of cutaneous hyperreactivity in Behçet's disease. Br J Dermatol (1976) 1.21
Epidemiology of nosocomial acquisition of Candida lusitaniae. J Clin Microbiol (1992) 1.21
Identification of Candida species by randomly amplified polymorphic DNA fingerprinting of colony lysates. J Clin Microbiol (1997) 1.21
Syphilitic posterior uveitis: correlative findings and significance. Clin Infect Dis (2001) 1.19
Candida vaginitis: self-reported incidence and associated costs. Sex Transm Dis (2000) 1.19
Evaluation of the painful prosthetic joint. Relative value of bone scan, sedimentation rate, and joint aspiration. J Arthroplasty (1991) 1.18
Comparison of ketoconazole, Bay N7133, and Bay L9139 in the treatment of experimental vaginal candidiasis. Antimicrob Agents Chemother (1983) 1.18
Adherence of bacteria to vaginal epithelial cells at various times in the menstrual cycle. Infect Immun (1981) 1.17
Long-term follow-up of patients with bacterial vaginosis treated with oral metronidazole and topical clindamycin. J Infect Dis (1993) 1.16
Vaginal-associated immunity in women with recurrent vulvovaginal candidiasis: evidence for vaginal Th1-type responses following intravaginal challenge with Candida antigen. J Infect Dis (1997) 1.15
Experimental aspergillus endocarditis in rabbits. J Lab Clin Med (1975) 1.15
Comparison of itraconazole and ketoconazole in the treatment of experimental candidal vaginitis. Antimicrob Agents Chemother (1984) 1.14
Role of antifungal drug resistance in the pathogenesis of recurrent vulvovaginal candidiasis. J Med Vet Mycol (1997) 1.14
Metronidazole-resistant vaginal trichomoniasis--an emerging problem. N Engl J Med (1999) 1.13
Polymorphonuclear leukocyte and monocyte chemoattractants produced by human fibroblasts. J Clin Invest (1979) 1.10
Karyotyping of Candida albicans isolates obtained longitudinally in women with recurrent vulvovaginal candidiasis. J Infect Dis (1994) 1.10
Ulcerative colitis in the South African Bantu. Gut (1970) 1.08
Evolution of vaginal Candida species recovered from human immunodeficiency virus-infected women receiving fluconazole prophylaxis: the emergence of Candida glabrata? Terry Beirn Community Programs for Clinical Research in AIDS (CPCRA). Clin Infect Dis (1999) 1.06
Transmission of uropathogens between sex partners. J Infect Dis (1997) 1.05
Cutaneous hyperreactivity in Behçet's disease. Dermatologica (1973) 1.05
Current debate on the use of antibiotic prophylaxis for caesarean section. BJOG (2011) 1.05
Cefoperazone treatment of experimental endocarditis. Antimicrob Agents Chemother (1981) 1.04
Evolution of antifungal susceptibility among Candida species isolates recovered from human immunodeficiency virus-infected women receiving fluconazole prophylaxis. Clin Infect Dis (2001) 1.03
Double-blind comparison of phlebitis produced by cephalothin infusions with buffered and unbuffered diluents. Antimicrob Agents Chemother (1974) 1.03
Urinary tract infection among women aged 40 to 65: behavioral and sexual risk factors. J Clin Epidemiol (2001) 1.03
Effect of acute alcohol intoxication on granulocyte mobilization and kinetics. Blood (1978) 1.03
Pancreatic ascites treated by irradiation of pancreas. Br Med J (1971) 1.02
Candida-specific systemic cell-mediated immune reactivities in human immunodeficiency virus-positive persons with mucosal candidiasis. J Infect Dis (2000) 1.02
Parvovirus B19 infection in human pregnancy. BJOG (2010) 1.02
In vitro activity and pharmacokinetics in patients of cefamandole, a new cephalsoporin antibiotic. Antimicrob Agents Chemother (1975) 1.01
High-frequency, in vitro reversible switching of Candida lusitaniae clinical isolates from amphotericin B susceptibility to resistance. Antimicrob Agents Chemother (1999) 1.01
Effects of systemic cell-mediated immunity on vaginal candidiasis in mice resistant and susceptible to Candida albicans infections. Infect Immun (1995) 1.01
Comparison of bacterial and fungal adherence to vaginal exfoliated epithelial cells and human vaginal epithelial tissue culture cells. Infect Immun (1982) 1.00
In vitro activity of a new pneumocandin antifungal agent, L-733,560 against azole-susceptible and -resistant Candida and Torulopsis species. Antimicrob Agents Chemother (1995) 1.00
Histiocytic necrotizing lymphadenitis (Kikuchi's disease): in situ end-labeling, immunohistochemical, and serologic evidence supporting cytotoxic lymphocyte-mediated apoptotic cell death. Mod Pathol (1997) 1.00